Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion. The drugmaker ...

Lilly's profit doubled in the fourth quarter, driven by its diabetes and obesity treatments Mounjaro and Zepbound, while ...

Lilly didn’t mince words about what sparked that growth, pointing to an impressive 60% sales leap for its type 2 diabetes blockbuster Mounjaro, which brought home $3.5 billion over the last ...

Shares rise nearly 5% after upbeat forecast Drugmaker suggests demand for Zepbound and Mounjaro remains strong Lilly forecast earnings of $22.50 to $24.00 per share on an adjusted basis this year ...

Sales of Lilly’s top-selling product, the diabetes treatment Mounjaro, jumped 60% to $3.53 billion in the final quarter of 2024 while its obesity treatment counterpart Zepbound brought in $1.9 ...